IP Library Granted Patent US 11,377,673
Granted Patent B2
US 11,377,673 · App. 17/091,599 · Granted Jul 5, 2022

Engineered imine reductases and methods for the reductive amination of ketone and amine compounds

Inventors: Haibin Chen (Beijing, CN); Steven J. Collier (Concord, MA); Jovana Nazor (Milpitas, CA); Joly Sukumaran (Singapore, SG); Derek Smith (Singapore, SG); Jeffrey C. Moore (Westfield, NJ); Gregory Hughes (Scotch Plains, NJ); Jacob Janey (New York, NY); Gjalt W. Huisman (Redwood City, CA); Scott J. Novick (Palo Alto, CA); Nicholas J. Agard (San Francisco, CA); Oscar Alvizo (Fremont, CA); Gregory A. Cope (Menlo Park, CA); Wan Lin Yeo (Singapore, SG); Stefanie Ng Minor (Redwood City, CA)
Assignee: Codexis, Inc.
C12P13/02C12N9/0028C12P13/001C12P13/04C12P13/06C12P17/10C12P17/12C12P17/165C12P17/185C12P17/188C12Y105/01C12Y105/01023C12Y105/01024C12Y105/01028Y02P20/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,377,673
App. No.
17/091,599
Granted
Jul 5, 2022
Kind
B2
Abstract

The present disclosure provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.

Claims (22)

1. An engineered polypeptide having imine reductase activity, wherein said polypeptide has at least 90% sequence identity to SEQ ID NO:2, and comprises a substitution at a position corresponding to position 111 of SEQ ID NO:2, wherein the amino acid at position 111 has been replaced with a non-polar, polar, or basic residue.

2. The engineered polypeptide having imine reductase activity of claim 1 , wherein said polypeptide has at least 90% sequence identity to SEQ ID NO:2, wherein the amino acid at the position corresponding to position 111 of SEQ ID NO:2 has been replaced with methionine, arginine, glutamine, or serine.

3. The engineered polypeptide of claim 1 , wherein said polypeptide is capable of converting substrate compound (1a) pyruvate,

and substrate compound (2b) butylamine

to product compound (3b), N-2-(butylamino)propanoic acid,

under suitable reaction conditions.

4. The engineered polypeptide of claim 1 , wherein said polypeptide is capable of converting substrate compound (1b) cyclohexanone,

and substrate compound (2a) L-norvaline

to product compound (3c), (S)-2-(cyclohexylamino)pentanoic acid,

under suitable reaction conditions.

5. The engineered polypeptide of claim 1 , wherein said polypeptide is capable of converting substrate compound (1b) cyclohexanone,

and substrate compound (2b) butylamine

to product compound (3d), N-butylcyclohexanamine,

under suitable reaction conditions.

6. The engineered polypeptide of claim 1 , wherein said polypeptide is capable of converting substrate compound (1i),

and substrate compound (2b)

to product compound (3n),

under suitable reaction conditions.

7. The engineered polypeptide of claim 1 , wherein said polypeptide is capable of converting substrate compound (1j),

and substrate compound (2b)

to product compound (3o),

under suitable reaction conditions.

Assignments (1)
SECURITY INTEREST Recorded Feb 15, 2024
From: CODEXIS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 066600/0650 →
Continuity (15)
Continuation 17002671 · Aug 25, 2020
Continuation 16655547 · Oct 17, 2019
Continuation 16391036 · Apr 22, 2019
Continuation 16195480 · Nov 19, 2018
Division 16054843 · Aug 3, 2018
Continuation 15899834 · Feb 20, 2018
Continuation 15792446 · Oct 24, 2017
Continuation 15710462 · Sep 20, 2017
Continuation 15605061 · May 25, 2017
Continuation 15286900 · Oct 6, 2016
Continuation 15048887 · Feb 19, 2016
Continuation 14887943 · Oct 20, 2015
Division 13890944 · May 9, 2013
Provisional Application 61646100 · May 11, 2012
Related Publication 20210054422A1 · Feb 25, 2021
Cited By (2)
US 12,215,368 US 12,421,532